Evidence map›Paper›PMID 27280691›Full record

ArticleGenetics2016

The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.

Nithya Kartha, Lishuang Shen, Carolyn Maskin, Marsha Wallace, John C Schimenti

Open access · bronzeAbstract read
In one paragraph

Article in Genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nithya KarthaDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853.
Lishuang ShenDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853.
Carolyn MaskinDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853.
Marsha WallaceDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853.
John C SchimentiDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853 jcs92@cornell.edu.
Cornell University · US

Funding

Evaluation of NF1 as a Major Breast Cancer DriverR21CA175961 · NCI · CORNELL UNIVERSITY · PI SCHIMENTI, JOHN C · 2013 to 2014
$364k
NCI NIH HHS R21 CA175961
6 · The paper itself

Abstract

Human cancer genome studies have identified the SWI/SNF chromatin remodeling complex member ARID1A as one of the most frequently altered genes in several tumor types. Its role as an ovarian tumor suppressor has been supported in compound knockout mice. Here, we provide genetic and functional evidence that Arid1a is a bona fide mammary tumor suppressor, using the Chromosome aberrations occurring spontaneously 3 (Chaos3) mouse model of sporadic breast cancer. About 70% of mammary tumors that formed in these mice contained a spontaneous deletion removing all or part of one Arid1a allele. Restoration of Arid1a expression in a Chaos3 mammary tumor line with low Arid1a levels greatly impaired its ability to form tumors following injection into cleared mammary glands, indicating that ARID1A insufficiency is crucial for maintenance of these Trp53-proficient tumors. Transcriptome analysis of tumor cells before and after reintroduction of Arid1a expression revealed alterations in growth signaling and cell-cycle checkpoint pathways, in particular the activation of the TRP53 pathway. Consistent with the latter, Arid1a reexpression in tumor cells led to increased p21 (Cdkn1a) expression and dramatic accumulation of cells in G2 phase of the cell cycle. These results not only provide in vivo evidence for a tumor suppressive and/or maintenance role in breast cancer, but also indicate a potential opportunity for therapeutic intervention in ARID1A-deficient human breast cancer subtypes that retain one intact copy of the gene and also maintain wild-type TRP53 activity.

Indexed as

AnimalsBreast NeoplasmsChromatinChromatin Assembly and DisassemblyCyclin-Dependent Kinase Inhibitor p21DNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticHumansMammary Neoplasms, AnimalMiceMutationNuclear ProteinsTranscription FactorsTumor Suppressor Protein p53Arid1a protein, mouseARID1B protein, humanCdkn1a protein, mouseChromatinCyclin-Dependent Kinase Inhibitor p21DNA-Binding ProteinsNuclear ProteinsTranscription FactorsTumor Suppressor Protein p53Arid1abreast cancercell cyclemousesenescencetumor suppressor

Identifiers

PMID27280691
PMCPMC4981264
OpenAlexW2408795902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.